Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.79 |
| ▸ | MAPT | P10636 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.79 |
| ▸ | HPGD | P15428 | 7/20 | 0.79 |
| ▸ | BLM | P54132 | 6/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.79 |
| ▸ | TP53 | P04637 | 5/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.79 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrphostin 23 SCHEMBL29360636 | 0.89 | EGFR (1.00) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| Tyrphostin 23 SCHEMBL241922 | 0.89 | EGFR (1.00) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL10144263 | 0.81 | EGFR (0.78) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL25736025 | 0.79 | MEN1 (0.77) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL10144273 | 0.79 | MAPT (0.84) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL13060220 | 0.77 | EGFR (0.77) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL25736028 | 0.75 | EGFR (0.61) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL876645 | 0.74 | EGFR (0.67) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL876644 | 0.74 | EGFR (0.67) | EGFRKDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL25736027 | 0.73 | EGFR (0.83) | EGFRKDM4EALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | EGFR 2861/4885KDM4E 4643/4885ALDH1A1 1572/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | EGFR 3560/4885KDM4E 2788/4885ALDH1A1 1238/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | EGFR 220/4885KDM4E 2301/4885ALDH1A1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.